摘要
阿尔茨海默病(AD)是一种以脑内β-淀粉样蛋白(Aβ)逐渐沉积形成老年斑和tau蛋白过度磷酸化形成神经原纤维缠结为主要病理特征的神经退行性疾病。脑铁代谢紊乱促进阿尔茨海默病的发病进程,铁代谢异常能够促进AD脑内Aβ的沉积、tau蛋白过度磷酸化以及氧化应激反应等神经病理过程;而金属离子螯合剂如去铁敏等,可通过调节脑内铁离子代谢平衡,阻止Aβ的产生、tau蛋白磷酸化并改善学习记忆能力。乳铁蛋白(lactoferrin,LF)是一种具有铁螯合和抗炎作用的糖蛋白,在AD患者和转基因小鼠大脑Aβ斑块和神经原纤维缠结内均有明显表达,提示LF可能具有抑制AD脑内神经病理特征的产生的作用。因此,LF可能成为防治AD的候选药物之一。
Alzheimer＇s disease（AD） is a neurodegenerative disorder characterized with β -amyloid protein（A β ） deposition and tau hyperphosphorylation in the brain. The brain iron dyshomeostasis is involved in the progress of AD, abnormal iron metabolism accelerates A β deposition and tau hyperphosphorylation in AD brain. Whereas, metal chelators such as desferrioxamine, may inhibit A β deposition and tau hyperphosphorylation and ameliorate memory injury, through regulating brain iron homeostasis. Lactoferrin（LF） is an iron-binding protein and an inflammatory modulator, abundant in A β plaques and tau-containing neurofibriUary tangles in the brain of AD patient and transgenic mouse, LF may play an important role in inhibiting the formation of AD pathology, and a potential therapeutic strategy for prevention and treatment of AD.
出处
《解剖科学进展》
2015年第6期667-669,673,共4页
Progress of Anatomical Sciences
基金
教育部基本科研业务费重大项目(120820001)
东北大学第九批"大学生创新训练计划"项目(151166)
